CTOs on the Move

Havas Health

www.havashealth.com

 
Havas Health houses Havas Life (formerly known as Euro RSCG Life), Health4brands (H4B), and Havas Lynx, three wholly-owned Health and Communications Networks, and defines policies and processes for the entire group. Its customer-centric approach has the talent, tenacity and technology that companies, brands and people need to thrive in today`s world.
  • Number of Employees: 250-1000
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Similar Companies

Equipment Placement Svc

Equipment Placement Svc is a Streetman, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cognecy Solutions

Cognecy Solutions, LLC is a Mckinney, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

University of Connecticut Health Center

The UConn Health Center offers an impressive range of clinical services by more than 350 physicians in over 50 specialties on an outpatient basis and on an inpatient basis at John Dempsey Hospital.

Asterand, plc

Asterand, plc is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Asterand, plc is based in Detroit, MI. You can find more information on Asterand, plc at www.asterand.com

OncoGenex

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address treatment resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical Industries Ltd. have entered a global collaboration and licensing agreement to develop and commercialize OncoGenex' lead drug candidate, custirsen. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer and in patients with advanced, unresectable non-small cell lung cancer. Apatorsen is in Phase 2 clinical development and OGX-225 is currently in pre-clinical development.